LEADER 07358nam 2200553 450 001 9910616209103321 005 20230426002753.0 010 $a3-031-10662-8 035 $a(MiAaPQ)EBC7107442 035 $a(Au-PeEL)EBL7107442 035 $a(CKB)24996009800041 035 $a(PPN)265862264 035 $a(EXLCZ)9924996009800041 100 $a20230303d2022 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aLung cancer screening $epractical aspects for primary care /$fedited by Janelle V. Baptiste, Richard M. Schwartzstein, Carey C. Thomson 210 1$aCham, Switzerland :$cSpringer,$d[2022] 210 4$d©2022 215 $a1 online resource (131 pages) 311 08$aPrint version: Baptiste, Janelle V. Lung Cancer Screening Cham : Springer International Publishing AG,c2022 9783031106613 320 $aIncludes bibliographical references and index. 327 $aIntro -- Introduction -- Contents -- Chapter 1: Epidemiology of Lung Cancer and Risk Factors -- 1.1 Epidemiology of Lung Cancer -- 1.1.1 Incidence -- 1.1.2 Mortality -- 1.1.3 Stage at Presentation -- 1.1.4 Histological Subtypes -- 1.2 Lung Cancer Risk Factors -- 1.2.1 Demographic Factors -- 1.2.2 Smoking -- 1.2.3 Passive Smoking -- 1.2.4 E-Cigarettes -- 1.2.5 Air Pollution -- 1.2.6 Radon -- 1.2.7 Asbestos -- 1.2.8 Infection -- 1.2.9 Genetics and Family History -- 1.3 Conclusion -- References -- Chapter 2: Health Disparities in Lung Cancer Screening -- 2.1 Overview of Health Disparities in Lung Cancer -- 2.2 The Landscape of Health Disparities in Lung Cancer Screening -- 2.2.1 Disparities Associated with Patient Demographics Including Race and Gender -- 2.2.2 The Role of Social Determinants of Health (SDOH) -- 2.3 Barriers to Lung Cancer Screening -- 2.3.1 Barriers to Lung Cancer Screening That Act at the Health Policy Level -- 2.3.2 Barriers to Lung Cancer Screening That Act at the Health System Level -- 2.3.3 Barriers to Lung Cancer Screening That Act at the Patient Level -- 2.3.4 Barriers to Lung Cancer Screening That Act at the Health Care Provider Level -- 2.4 Overcoming Disparities in Lung Cancer Screening -- References -- Chapter 3: Best Practices in Lung Cancer Screening -- 3.1 Evidence Base for Lung Cancer Screening -- 3.1.1 Introduction -- 3.1.2 Measuring Benefits and Harms of Screening -- 3.1.3 Screening Modalities -- 3.1.3.1 Chest Radiography and Sputum Cytology -- 3.1.3.2 Low-Dose CT Scan -- Observational Studies -- 3.1.3.3 Randomized Clinical Trials -- National Lung Screening Trial -- European Randomized Lung Cancer Screening Trials -- NELSON Trial -- 3.1.4 Patient Selection -- 3.1.5 Evidence of Potential Harms -- 3.1.6 Shared Decision-Making Evidence in Lung Cancer Screening -- 3.1.7 Cost-Effectiveness of Lung Cancer Screening. 327 $a3.1.8 Smoking and Lung Cancer Screening -- 3.1.9 Non-lung nodule Findings -- 3.1.10 Evidence Needs -- 3.1.11 Conclusion -- 3.2 Quality Indicators in Lung Cancer Screening Programs -- 3.2.1 Challenges in Developing Quality Metrics in Lung Cancer Screening -- 3.2.2 Expert Consensus in Measuring Program Quality in Lung Cancer Screening -- 3.2.3 National Trends in Screening Rates, Disparities, and Targets -- 3.3 Structure and Governance -- 3.3.1 Steering Committee Governance of CT Lung Screening Programs -- 3.3.2 Program Design -- 3.3.3 Provider Continuing Education -- 3.3.4 Community Outreach -- 3.3.5 Measuring Outcomes -- 3.3.6 Research Oversight -- 3.4 Navigation -- 3.4.1 Introduction -- 3.4.2 Office/Department-Based Navigation -- 3.4.3 Lung Cancer Screening Program Navigation -- 3.4.4 The Benefit of Nursing Navigation in Cancer Screening -- 3.4.5 Navigating Lung Cancer Screening in the Electronic Medical Record -- 3.4.6 Navigation Summary -- References -- Chapter 4: Implementing Lung Cancer Screening in Clinical Practice -- 4.1 Lung Cancer Screening Eligibility Criteria and Confirmation of Eligibility -- 4.1.1 Current Eligibility Criteria for Lung Cancer Screening -- 4.1.2 Determining and Ensuring Eligibility for Lung Cancer Screening (LCS) -- 4.1.3 Suggested Areas of Research -- 4.2 Barriers to Implementing Lung Cancer Screening (LCS) in Clinical Practice -- 4.2.1 Discussing Barriers to Implementation of LCS in Primary Care -- 4.2.2 Lung Cancer Screening Is Complex and Costly -- 4.2.3 External Influences Is a Barrier to Lung Cancer Screening Implementation -- 4.2.4 Future Direction -- 4.3 Integration of Lung Cancer Screening into the Electronic Health Record -- 4.3.1 Areas of Focus for Leveraging the EHR -- 4.3.1.1 Documentation of Lung Cancer Risk Factors -- 4.3.2 EHR Support for Identifying LCS-Eligible Individuals. 327 $a4.3.3 Tracking LDCT Findings for Follow-Up -- 4.3.4 Research Gaps -- 4.3.5 Future Directions -- 4.4 Insurance Coverage and Prior Authorization of Lung Cancer Screening -- 4.4.1 Private Insurance Coverage -- 4.4.2 Medicare Coverage -- 4.4.3 Medicaid Coverage -- 4.4.4 Prior Authorization -- References -- Chapter 5: Innovations in Integrating Smoking Cessation and the Shared Decision-Making Discussion into Lung Cancer Screening -- 5.1 Components of a Shared Decision-Making Discussion -- 5.2 Challenges in Shared Decision-Making Decisions: Embracing Uncertainty -- 5.2.1 Biology of the Tumor -- 5.2.2 Concept of False Positives -- 5.2.3 Relative Versus Absolute Risk Reduction -- 5.2.4 Addressing Uncertainty in Lung Cancer Screening -- 5.3 Smoking Cessation -- 5.3.1 Evidence-Based Tobacco Treatment -- 5.3.2 Tobacco Therapy and the Shared Decision -- 5.3.3 Personalized Risk Assessment to Support Quitting -- 5.3.4 Barriers to Quitting -- 5.4 Innovation in Lung Screening and Decision Support Tools -- 5.4.1 What Is Innovation? -- 5.4.2 Current Educational Tools Are Lacking -- 5.4.3 Experiential Learning and Understanding Pulmonary Nodules -- 5.4.4 Measuring the Effectiveness of a Tactile Lung Nodule Tool -- 5.4.5 Innovations for Rural Engagement and Supporting Quitting -- 5.4.6 Virtual Reality: Next Generational Teaching Tool -- References -- Chapter 6: Lung Cancer Screening Results and Tracking -- 6.1 Ordering a LCS CT -- 6.2 Standardized Reporting Protocols and National Registry Requirements -- 6.3 Managing Screening Findings on Lung Cancer Screening CTs -- 6.4 Managing Incidental Findings on Lung Cancer Screening CT -- 6.5 Updates in Lung Cancer Screening Technology -- 6.6 Women and Lung Cancer Screening -- References -- Index. 606 $aLungs$xCancer$xDiagnosis 606 $aLung Neoplasms$xdiagnostic imaging 606 $aLung Neoplasms$xdiagnosis 606 $aEarly Detection of Cancer 606 $aDiagnostic Screening Programs 615 0$aLungs$xCancer$xDiagnosis. 615 2$aLung Neoplasms$xdiagnostic imaging. 615 2$aLung Neoplasms$xdiagnosis. 615 2$aEarly Detection of Cancer. 615 2$aDiagnostic Screening Programs. 676 $a262 702 $aBaptiste$b Janelle V. 702 $aSchwartzstein$b Richard M. 702 $aThomson$b Carey C. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910616209103321 996 $aLung Cancer Screening$92939515 997 $aUNINA